Eléments de l'association
|  |
List of bibliographic references
Number of relevant bibliographic references: 23.| Ident. | Authors (with country if any) | Title |
|---|---|---|
| 000937 | A. Hadj Tahar [Canada] ; R. Grondin [Canada] ; L. Gregoire [Canada] ; F. Calon [Canada] ; T. Di Paolo [Canada] ; P. J. Bedard [Canada] | New insights in Parkinson's disease therapy: Can levodopa-induced dyskinesia ever be manageable |
| 000B60 | M. Goulet [Canada] ; R. Grondin [Canada] ; M. Morissette [Canada] ; S. Maltais [Canada] ; P. Falardeau [Canada] ; P. J. Bedard [Canada] ; T. Di Paolo [Canada] | Regulation by chronic treatment with cabergoline of dopamine D1 and D2 receptor levels and their expression in the striatum of Parkinsonian-Monkeys |
| 000B68 | M. Grandbois [Canada] ; M. Morissette [Canada] ; S. Callier [Canada, France] ; T. Di Paolo [Canada] | Ovarian steroids and raloxifene prevent MPTP-induced dopamine depletion in mice |
| 000B96 | M. Cyr [Canada] ; F. Calon [Canada] ; M. Morissette [Canada] ; M. Grandbois [Canada] ; S. Callier [Canada, France] ; T. Di Paolo [Canada] | Drugs with estrogen-like potency and brain activity : Potential therapeutic application for the CNS |
| 000C13 | F. Calon [Canada] ; M. Morissette [Canada] ; M. Goulet [Canada] ; R. Grondin [Canada] ; P. J. Blanchet [Canada] ; P. J. Bedard [Canada] ; T. Di Paolo [Canada] | 125I-CGP 64213 binding to GABAB receptors in the brain of monkeys : Effect of MPTP and dopaminomimetic treatments |
| 000C62 | R. Grondin [Canada] ; M. Goulet [Canada] ; M. Morissette [Canada] ; P. J. Bedard [Canada] ; T. Di Paolo [Canada] | Dopamine D1 receptor mRNA and receptor levels in the striatum of MPTP monkeys chronically treated with SKF-82958 |
| 000C69 | F. Calon [Canada] ; M. Morissette [Canada] ; M. Goulet [Canada] ; R. Grondin [Canada] ; P. J. Blanchet [Canada] ; P. J. Bedard [Canada] ; T. Di Paolo [Canada] | Chronic D1 and D2 dopaminomimetic treatment of MPTP-denervated monkeys : effects on basal ganglia GABAA/ benzodiazepine receptor complex and GABA content |
| 000D94 | M. Goulet [Canada] ; M. Morissette [Canada] ; F. Calon [Canada] ; P. J. Blanchet [Canada] ; P. Falardeau [Canada] ; P. J. Bedard [Canada] ; T. Di Paolo [Canada] | Continuous or pulsatile chronic D2 dopamine receptor agonist (U91356A) treatment of drug-naive 4-phenyl-1,2,3,6-tetrahydropyridine monkeys differentially regulates brain D1 and D2 receptor expression : In situ hybridization histochemical analysis |
| 000E22 | J.-J. Soghomonian [Canada] ; S. Pedneault [Canada] ; P. J. Blanchet [Canada] ; M. Goulet [Canada] ; T. Di Paolo [Canada] ; P. J. Bedard [Canada] | L-DOPA regulates glutamate decarboxylases mRNA levels in MPTP-treated monkeys |
| 000E28 | M. Goulet [Canada] ; R. Grondin ; P. J. Blanchet ; P. J. Bedard ; T. Di Paolo [Canada] | Dyskinesias and tolerance induced by chronic treatment with a D1 agonist administered in pulsatile or continuous mode to not correlate with changes of putaminal D1 receptors in drug-naive MPTP monkeys |
| 000E36 | R. Grondin [Canada] ; M. Goulet [Canada] ; T. Di Paolo [Canada] ; P. J. Bedard [Canada] | Cabergoline, a long-acting dopamine D2-like receptor agonist, produces a sustained antiparkinsonian effect with transient dyskinesias in parkinsonian drug-naive primates |
| 000E58 | F. Calon [Canada] ; M. Goulet [Canada] ; P. J. Blanchet ; J. C. Martel [Canada] ; M. F. Piercey ; P. J. Bedard ; T. Di Paolo [Canada] | Levodopa or D2 agonist induced dyskinesia in MPTP monkeys : correlation with changes in dopamine and GABAA receptors in the striatopallidal complex |
| 000E66 | C. Gagnon [Canada] ; B. Gomez-Mancilla ; R. Markstein ; P. J. Bedard ; T. Di Paolo [Canada] | Effect of adding the D-1 agonist CY 208-243 to chronic bromocriptine treatment of MPTP-monkeys : regional changes of brain dopamine receptors |
| 000F44 | B. Gomez-Mancilla [Canada] ; R. Boucher ; C. Gagnon ; T. Di Paolo ; R. Markstein ; P. J. Bedard | Effect of adding the D1 agonist CY 208-243 to chronic bromocriptine treatment. I: Evaluation of motor parameters in relation to striatal catecholamine content and dopamine receptors |
| 000F50 | C. Gagnon [Canada] ; B. Gomez-Mancilla ; P. J. Bedard ; T. Di Paolo [Canada] | Chronic CY 208-243 treatment of MPTP-monkeys causes regional changes of dopamine and GABAA receptors |
| 000F59 | L. Rioux [Canada] ; C. Gagnon ; D. P. Gaudin [Canada] ; T. Di Paolo ; P. J. Bedard [Canada] | A fetal nigral graft prevents behavioral supersensitivity associated with repeated injections of L-dopa in 6-OHDA rats. Correlation with D1 and D2 receptors |
| 001063 | C. Rouillard ; P. J. Bedard ; T. Di Paolo | Effects of chronic treatment of MPTP monkeys with bromocriptine alone or in combination with SKF 38393 |
| 001064 | C. Gagnon ; P. J. Bedard ; T. Di Paolo | Effect of chronic treatment of MPTP monkeys with dopamine D-1 and/or D-2 receptor agonists |
| 001071 | C. Harnois ; T. Di Paolo | Decreased dopamine in the retinas of patients with Parkinson's disease |
| 001097 | C. Harnois ; G. Marcotte ; T. Di Paolo | Different sensitivities to MPTP toxicity in primate nigrostriatal and retinal dopaminergic systems: electrophysiological and biochemical evidence |
| 001126 | P. Falardeau ; S. Bouchard ; P. J. Bedard ; R. Boucher ; T. Di Paolo | Behavioral and biochemical effect of chronic treatment with D-1 and/or D-2dopamine agonists in MPTP monkeys |
| 001171 | T. Di Paolo ; P. Bedard ; M. Daigle ; R. Boucher | Long-term effects of MPTP on central and peripheral catecholamine and indoleamine concentrations in monkeys |
| 001184 | P. J. Bedard ; T. Di Paolo ; P. Falardeau ; R. Boucher | Chronic treatment with L-DOPA, but not bromocriptine induces dyskinesia in MPTP-Parkinsonian monkeys. Correlation with [3H]spiperone binding |
| This area was generated with Dilib version V0.6.29. |  |